Skip to main content
. 2024 Jan;17(1):15–23.

TABLE 1.

Outcomes of Reviewed Articles

AUTHOR, YEAR STUDY DRUG, DOSE N KEY FINDINGS
Boineau, 1988 MPFF 1000mg QD v. placebo 36

  • Improvement or resolution of reversible trophic skin disorders*
Greney, 1992 MPFF 1000mg QD 3240

  • CVI skin changes improved in 46% of patients presenting with dermatofibrosclerosis and in 66% with gravitational dermatitis

  • Ulcer healing improved in 62% of patients
Guilhou, 1997 MPFF 1000mg QD v. placebo 107

  • Number of ulcers healed: 32% v. 13%*

  • Improvement in leg heaviness and time to heal: treatment < placebo *
Glinski, 1999 MPFF 2000mg QD + SOC v. SOC alone 140

  • Number of ulcers healed: 46.5% v. 27.5%*

  • Ulcer SA reduction: 80% v. 65%*

  • Symptom reduction (%): Discomfort 64.8* v. 38.3; Pain: 57 v. 43; Heaviness: 57 v. 53; Night cramps: 80 v. 67
Cesarone, 2002 HR 2000mg QD + SOC v. placebo + SOC 40

  • Symptom score on 11-point analog scale: -5.4* v. +0.2
Incandela, 2002 HR 2000mg QD + SOC v. placebo + SOC 60

  • Symptom score on 11-point analog scale: -6.0* v. -1.1
Roztocil, 2003 MPFF 1000mg QD + SOC v. SOC alone 150

  • Number ulcers healed: 64.6%* v. 41.2%

  • Days to heal: 137* v. 166

  • Change in ulcer SA: 77%* v. 69%

  • Improvement in leg heaviness*
Serra, 2014 Axaven® + SOC v. SOC alone 36

  • Number ulcers healed at 12 months: 83.8% v. 60.56%

  • Ulcer recurrence at EOS: 26.76%* v. 59.15%*
Carpentier, 2017 MPFF 1000mg QD or 2 tablets MPFF 500mg BID 1139

  • Improvement in lower limb discomfort*

  • Improvement in leg pain, leg heaviness, QoL
Kirienko, 2019 MPFF 1000 mg QD vs. MPFF 500 mg BID 174

  • Improvement in leg pain*
Maggioli, 2019 MPFF 1000 mg QD vs. MPFF 500 mg BID 256

  • Improvement in lower limb discomfort*

  • Improvement in leg pain and heaviness*

  • Improvement in QoL*
Serra, 2021 μsmin® Plus 450mg QD v. placebo 72

  • Change in mid-calf circumference: 4.67%* v. 0.32%

  • QoL assessed by GIS: -25.95* v. -5.5 VAS: reduction T* > P

  • VCSS: improvement T* > P
Bogachev, 2022 MPFF 1000mg QD + SOC 365

  • Improvement in subcutaneous adipose tissue thickness, VCSS and VAS scores*

μsmin® Plus: a diosmin preparation with enhanced bioavailability; Axaven®: diosmin 1000mg, hesperidin 100mg, rutin 300mg, astaxanthin 5mg, horse chestnut, 50mg, blueberry 160mg and althea 100mg; GIS: global index score; HR: Paroven, Venoruton; 0-(β-hydroxyethyl)-rutosides); QD: daily; QoL: quality of life; SA: surface area; SOC: standard of care (compression ± localized topical therapy); VAS: visual analog scale; VCSS: venous clinical severity score